New Zealand markets closed

Avenue Therapeutics, Inc. (ATXI)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.1250-0.0105 (-7.75%)
At close: 04:00PM EDT
0.1255 +0.00 (+0.40%)
After hours: 06:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1355
Open0.1390
Bid0.1300 x 100
Ask0.1256 x 800
Day's range0.1152 - 0.1400
52-week range0.1130 - 1.2800
Volume2,296,297
Avg. volume1,646,566
Market cap5.533M
Beta (5Y monthly)-0.26
PE ratio (TTM)N/A
EPS (TTM)-0.9800
Earnings date10 May 2024 - 14 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.75
  • GlobeNewswire

    Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

    MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event wi

  • GlobeNewswire

    Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

    - Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical data at American Epilepsy Society (AES) and American Society for Experimental Neurotherapeutics (ASENT) Annual Meetings and in publication Drug Development Research - - Final agreement reached with FDA on study design and analysis approach for Phase 3 safety study of IV tramadol – MIAMI, March 18, 2024 (G

  • GlobeNewswire

    Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

    MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.